Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

141 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-04

Study Completion Date

2019-11-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonald Criteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Apathy in Dementia Methylphenidate Trial (ADMET)

NCT01117181

Apathy Alzheimer's Disease

COMPLETED PHASE2

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

NCT03811847

Alzheimer Dementia

COMPLETED PHASE4

Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

NCT06905587

Brain Tumor, Pediatric Cancer-related Fatigue Methylphenidate

RECRUITING PHASE3

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

NCT00228540

ADHD

COMPLETED PHASE3

Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD

NCT00214981

Attention Deficit/Hyperactivity Disorder ADHD

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonald Criteria.

Using a balanced Latin-square crossover design, subjects will be allocated, in a double-blind, randomized fashion, to one of the four treatment sequences (Figure 1): 1) amantadine, placebo, modafinil, methylphenidate; 2) placebo, methylphenidate, amantadine, modafinil; 3) modafinil, amantadine, methylphenidate, placebo; and 4) methylphenidate, modafinil, placebo and amantadine. Each medication will be titrated over four weeks to the participants' highest tolerated dose or the pre-defined highest dose. The dosing and titration schedule of the study medications are depicted in Figure 2. Each treatment period will be 6 weeks and there will be a 2-week washout period between each treatment period. At the beginning of the trial, a biostatistician at University of California, San Francisco (UCSF) will prepare a concealed allocation schedule, randomly assigning the four sequences, in blocks of 4, to a consecutive series of numbers and at the time of enrollment, each participant will be assigned the next consecutive number (and hence the sequence of study medications).

The primary endpoint of the study will be fatigue severity as measured by the MFIS score, between 26th and 35th day of each treatment period (while the patient is taking the maximal tolerated or target dose). The MFIS is a validated patient-reported outcome. The questionnaire will be administered remotely (through internet, phone or mailed forms) and the participants can answer the questions in few minutes while at home or at their work place. The questionnaire has been validated in English and Spanish.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fatigue in Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind, multicenter trial of 3 commonly used medications for treatment of Multiple Sclerosis related fatigue versus placebo in fatigued subjects with MS.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-blind

Intervention Type DRUG

1 placebo capsule increased to max of 2 capsules twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amantadine

100 mg of amantadine increased to 200 mg of amantadine, if tolerated

Intervention Type DRUG

Modafinil

100 mg of modafinil increased to 200 mg of modafinil, if tolerated

Intervention Type DRUG

Methylphenidate

5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated

Intervention Type DRUG

Placebos

1 placebo capsule increased to max of 2 capsules twice daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years and older.
* Females of childbearing age must have a negative urine pregnancy test at baseline and use an effective method of contraception during the study.
* Diagnosis of MS (according to the 2010 McDonald criteria).
* Expanded Disability Status Scale (EDSS) score at the time of screening 0.0-7.0.
* Fatigue reportedly present and screening Modified Fatigue Impact Scale (MFIS) score more than 33.
* At least a two-week washout for any fatigue-related drug, including study medications.

Exclusion Criteria

* Neurodegenerative disorders other than relapsing or progressive MS.
* Breastfeeding or pregnant.
* History of coronary artery disease or congestive heart failure.
* Uncontrolled hypertension at screening (history of high blood pressure and screening systolic blood pressure \>160 or diastolic blood pressure\>100).
* Glomerular Filtration Rate (GFR) (glomerular filtration rate) \< 50.
* Abnormal liver function at screening (AST or Alanine Aminotransferase (ALT) more than twice the upper limit of normal).
* Terminal medical conditions.
* Currently treated for active malignancy.
* Planned surgery or move within 8 months of screening.
* Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).
* A history of intolerance or allergic or anaphylactic reaction to amantadine, modafinil, methylphenidate or any component of the preparation.
* Clinically unstable medical or psychiatric disorders that require acute treatment as determined by the PI.
* Concurrent use of monoamine oxidase inhibitors-B.
* Hypersensitivity/idiosyncrasy to sympathomimetic amines
* Inability to communicate or answer the questionnaires in English or Spanish.
* Severe untreated anemia (blood hemoglobin \<9gr/dl)
* History of untreated hypothyroidism
* History of untreated sleep apnea
* History of long QT syndrome, atrial fibrillation or tachyarrhythmias (other than sinus tachycardia)
* History of ischemic or hemorrhagic stroke
* History of glaucoma
* History of Tourette syndrome

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No